Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1372617 | Bioorganic & Medicinal Chemistry Letters | 2009 | 5 Pages |
A series of boron peptides 11, 13, 15 and 17 were designed and synthesized as proteasome inhibitors based on the structure of Belactosin C. Matteson homologation was a key step in the synthesis of the boron peptides. Compounds 11a and 13 showed significant inhibition of 20S proteasome chymotrypsin-like (β5) activity (IC50 = 0.28 and 0.51 μM, respectively). Furthermore, like PS-341, compound 11a increased the G2/M cell distribution. A biparametric cytofluorimetric analysis with FITC-labeled annexin V and propidium iodide showed induction of apoptosis by compound 11a at >1 μM concentrations of compound.
Graphical abstractA series of boron peptides were synthesized as inhibitors of the chymotrypsin-like (β5) activity of the 20S proteasome based around the structure of Belactosin C.Figure optionsDownload full-size imageDownload as PowerPoint slide